A Potential Novel Targeted Drug for the Treatment of Pulmonary Arterial Hypertension:Imatinib / 医药导报
Herald of Medicine
; (12): 262-266, 2024.
Article
in Zh
| WPRIM
| ID: wpr-1023708
Responsible library:
WPRO
ABSTRACT
Pulmonary hypertension has a high mortality rate,and although targeted therapy is available,it is still incurable,and the long-term prognosis for patients is poor.As a tyrosine kinase inhibitor,imatinib was approved for marketing in China in 2002 for the treatment of chronic myelogenous leukemia and other tumor diseases.In addition to the antitumor effects,imatinib was found to improve hemodynamics and exercise tolerance in patients with severe pulmonary arterial hypertension,but the safety was suboptimal.With the emergence of new formulations of imatinib targeted at the lungs,it is expected to become a new targeted drug for pulmonary arterial hypertension.
Full text:
1
Database:
WPRIM
Language:
Zh
Journal:
Herald of Medicine
Year:
2024
Document type:
Article